

## ORIGINAL ARTICLE

## Identifying undiagnosed or undertreated patients with familial hypercholesterolemia from the laboratory records of a tertiary medical center

### Tanı konmamış veya yeterli tedavi almayan ailevi hiperkolestrolemili hastaların bir üçüncü basamak sağlık merkezi laboratuvar kayıtlarından tespit edilmesi

Cem Haymana, M.D.,<sup>1</sup> Hamza Berlik, M.D.,<sup>2</sup> Yalçın Güneş, M.D.,<sup>2</sup> Orhan Enes Tunçöz, M.D.,<sup>2</sup> Cihat Aytekin, M.D.,<sup>2</sup> Zafer Tapıkara, M.D.,<sup>2</sup> Hüseyin Güzel, M.D.,<sup>2</sup> Özlem Öztürk, M.D.,<sup>3</sup> Cem Barçın, M.D.,<sup>4</sup> Taner Özgürtaş, M.D.,<sup>3</sup> Ömer Azal, M.D.,<sup>1</sup> Alper Sönmez, M.D.<sup>1</sup>

<sup>1</sup>Department of Endocrinology and Metabolism, Gülhane Training and Research Hospital, Ankara, Turkey

<sup>2</sup>Health Sciences University, Gülhane Faculty of Medicine, Ankara, Turkey

<sup>3</sup>Department of Biochemistry, Gülhane Training and Research Hospital, Ankara, Turkey

<sup>4</sup>Department of Cardiology, Gülhane Training and Research Hospital, Ankara, Turkey

#### ABSTRACT

**Objective:** Familial hypercholesterolemia (FH) is a life-threatening genetic disease associated with elevated low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease that is undiagnosed and undertreated around the world. This study aimed to examine the demographic characteristics, awareness, and treatment adherence of undiagnosed or undertreated FH patients based on laboratory records.

**Methods:** In a 16-month retrospective survey using laboratory records, patients with elevated LDL-C (>250 mg/dL) were identified (n=395). Patients younger than 18 years of age or with secondary causes of dyslipidemia were excluded (n=98). In all, 297 patients were called and asked to participate in a phone interview regarding their demographic characteristics, awareness of dyslipidemia, and treatment adherence.

**Results:** A total of 147 patients (mean age: 51.7±16.6 years; 59.2% female) completed the interview. The mean LDL-C level of the patients was 292.8±49.9 mg/dL. According to the Dutch Lipid Clinic Network criteria, 18.4% of the patients had definite FH, 66.0% had probable FH, and 15.6% had possible FH. Although the majority of the patients (93.9%) were aware of their high LDL-C level, only about half of them (n=75; 51.0%) were in treatment. Of all the patients who were interviewed, 21% (n=31) had never taken medication to lower their LDL-C, and 28% (n=41) had stopped taking a lipid-lowering drug.

**Conclusion:** This pilot study revealed that a significant number of FH patients were not taking statins despite having a very high LDL-C level. Nationwide detection of likely FH patients using hospital records and interviewing them via a phone survey may help to better understand and manage these high-risk patients.

#### ÖZET

**Amaç:** Ailevi hiperkolestrolemi (AH), düşük yoğunluklu lipoprotein kolesterol (LDL-K) yüksekliği ve erken koroner kalp hastalığı ile birlikte seyreden ve genellikle tanı konmayan veya yeterli tedavi almayan hayatı tehdit edici genetik bir hastalıktır. Bu çalışmada, biyokimya laboratuvar kayıtlarına dayanarak, tanı konmamış veya yeterli tedavi almayan AH'li hastaların demografik özelliklerinin, farkındalıklarının ve tedaviye uyumlarının araştırılması amaçlandı.

**Yöntemler:** Laboratuvar kayıtları kullanılarak yapılan 16 aylık geriye dönük çalışma sonucunda LDL-K değeri >250 mg/dL olan hastalar tespit edildi (n=395). On sekiz yaşından genç veya ikincil dislipidemi olan hastalar çalışma dışında bırakıldı (n=98). Sonuçta, 297 hasta telefonla arandı ve demografik özellikleri, dislipidemi farkındalıkları ve tedaviye uyumları hakkında sorular yöneltildi.

**Bulgular:** Çalışmaya katılmayı kabul eden toplam 147 hasta (ort. yaş 51.7±16.6 yıl, %59.2 kadın) ile görüşme yapıldı. Ortalama LDL-K düzeyleri 292.8±49.9 mg/dL bulundu. "Dutch Lipid Clinic Network" kriterlerine göre kesin, muhtemel ve olası AH'li hastaların oranları sırasıyla %18.4, %66.0 ve %15.6 olarak tespit edildi. Hastaların büyük bir kısmı (%93.9) yüksek LDL-K düzeylerine sahip olduklarının farkında olmalarına rağmen yalnızca yarısı (n=75, %51.0) tedavi almaktaydı. Görüşme yapılan hastaların %21'i (n=31) hiç tedavi almamış ve %28'i (n=41) ise lipid düşürücü ilaç kullanmayı bırakmıştı.

**Sonuç:** Bu pilot çalışma, çok yüksek LDL-K düzeylerine sahip olmalarına rağmen önemli oranda AH'li hastanın statin tedavisi almadığını ya da tedaviyi bıraktığını göstermektedir. Hastane kayıtlarından tespit edilen AH'li hastaların telefonla aranması ile yapılan bu çalışmanın ulusal düzeyde yaygınlaştırılması bu yüksek riskli hastalara ulaşılmasında ve bu hastaların yönetiminde yardımcı olabilir.

Received: May 16, 2017 Accepted: August 02, 2017 Online: November 17, 2017

Correspondence: Dr. Cem Haymana. Gülhane Eğitim ve Araştırma Hastanesi, Endokrinoloji ve Metabolizma Hastalıkları Kliniği, Ankara, Turkey.

Tel: +90 312 - 304 42 29 e-mail: cemhaymana@hotmail.com

© 2017 Turkish Society of Cardiology



**F**amilial hypercholesterolemia (FH) is an autosomal co-dominant condition associated with elevated low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease (CHD). Although the estimated prevalence of heterozygous FH is about 1/200-500, the majority of these individuals are currently undiagnosed or undertreated.<sup>[1]</sup> Unfortunately, the life expectancy is limited in FH patients who are not appropriately treated.<sup>[2]</sup> However, with the current treatment modalities, we are able to reduce elevated LDL-C levels and prevent the progression of atherosclerotic cardiovascular diseases.

Several different criteria are used to diagnose FH.<sup>[3]</sup> Organized efforts to screen and diagnose FH have helped to clarify the characteristics of these patients.<sup>[4-6]</sup> However, despite these efforts, a considerable number of FH patients are still undiagnosed or undertreated.<sup>[1]</sup> There are several reasons for this ignorance, such as a lack of awareness of the devastating nature of FH and fear of the side effects of statins.<sup>[7,8]</sup> In addition, the lack of universal, nationwide screening programs and insufficient electronic health records are other important limitations to the appropriate diagnosis, treatment, and follow-up of patients with FH. Identifying patients with a high LDL-C level using the health records of community laboratories may be a practical method of determining individuals with FH.<sup>[3,9,10]</sup>

There are emerging data about the prevalence of FH in different countries<sup>[6,11,12]</sup> and recent reports better define the characteristics of FH patients in different regions of the world.<sup>[4,5,13,14]</sup> However, the epidemiological data about FH patients in Turkey are insufficient.<sup>[15,16]</sup> This pilot study was designed to examine the demographical characteristics, awareness level, and treatment adherence of FH patients. Patients with a high LDL-C level were identified from the records of the central biochemistry laboratory of a tertiary care center.

## METHODS

### Participants and data collection

The study group was retrospectively selected from patients who were referred to the outpatient clinics of a tertiary medical center between January 2015 and April 2016 with a central laboratory measurement of LDL-C >250 mg/dL. This LDL-C cut-off was selected in order to enroll patients with probable FH and defi-

nite FH according to the Dutch Lipid Clinic Network (DLCN) criteria.

<sup>[17]</sup> The telephone numbers of the pa-

tients included in the study were obtained from the hospital records system. Patients who were excluded were those younger than 18 years of age and those with an International Classification of Diseases code for a potential secondary cause of hypercholesterolemia, such as hypothyroidism, nephrotic syndrome, or cholestasis. The study was performed in accordance with the ethical principles set forth in the Declaration of Helsinki and was approved by the institutional ethics committee (December 15, 2015; number: 497).

### Telephone questionnaire

Medical students called the patients and asked if they would be willing to participate in the study. During the interview, the students filled in an FH questionnaire, which included questions about demographic data, awareness of LDL-C level, history of lipid-lowering medication use, presence of cardiovascular disease, family history of hypercholesterolemia and cardiovascular disease, and daily habits, including smoking, diet, and exercise (Table 1).

### Defining familial hypercholesterolemia case status

Patients who agreed to participate in the phone interview were classified according to DLCN criteria for the clinical likelihood of FH.<sup>[17]</sup> The following modified version of the DLCN criteria and numerical score was used: Family history of a first-degree relative with known premature (55 years for men, 60 years for women) coronary artery disease (CAD) or vascular disease, and/or a first-degree relative with known hypercholesterolemia (1 point); personal history of premature CAD (ages as above; 2 points), or premature cerebral or peripheral vascular disease (ages as above; 1 point); LDL-C above 330 mg/dL (8 points), 250–329 mg/dL (5 points), 190–249 mg/dL (3 points), or 155–189 mg/dL (1 point). Two criteria of the original set, namely, the presence of tendon xanthoma or corneal arcus, either in the patient or in a first-degree relative, were excluded, as it was not possible to perform a physical examination. Participants were classified as follows: definite FH (score >8), probable FH (score 6–8 points), or possible FH (score 3–5 points).

#### Abbreviations:

CAD	Coronary artery disease
CHD	Coronary heart disease
DLCN	Dutch Lipid Clinic Network
FH	Familial hypercholesterolemia
LDL-C	Low-density lipoprotein cholesterol

**Table 1. Familial hypercholesterolemia telephone interview questionnaire**

Familial Hypercholesterolemia Telephone Questionnaire Form			
Age:			
Marital status:			
Place of birth:			
Smoking:	<input type="checkbox"/> I don't smoke	<input type="checkbox"/> I quit smoking (< 5 year)	<input type="checkbox"/> I smoke (cigarettes /day)
Alcohol:	<input type="checkbox"/> Never	<input type="checkbox"/> Rare (social)	<input type="checkbox"/> 1-2 times a week
	<input type="checkbox"/> 3-4 times a week	<input type="checkbox"/> 5-7 times a week	
Exercise:	<input type="checkbox"/> Never	<input type="checkbox"/> 1-2 days a week	<input type="checkbox"/> 3-4 days a week <input type="checkbox"/> 5-7 days a week
Diet:	<input type="checkbox"/> Makes an effort to eat healthily (low in saturated fat, high fiber)		
	<input type="checkbox"/> No specific effort made toward healthy eating		
1 - Do you know that you have high cholesterol?			
Yes	No		
2 - Are you still being treated for high cholesterol level?			
Yes (Drugs .....)			
No			
3- Have you been treated previously because of the high cholesterol level?			
Yes (Drugs .....)			
No			
4- If you were treated before, why was the treatment discontinued?			
Adverse effect	Own request	Other	
5- Do you have a atherosclerotic cardiovascular disease*?			
No	Yes (Age .....)		
6- Any other metabolic disease?		Drugs	
Obesity	.....		
Diabetes mellitus	.....		
Hypertension	.....		
Renal disease	.....		
Liver disease	.....		
Other	.....		
7- Do any of your first-degree relatives (father, mother, siblings) have atherosclerotic cardiovascular disease* at an early age (men: <55 years, Women <60 years)?			
Yes	No	Unknown	
8- Is there anyone else in your family who has a high cholesterol level like you?			
Yes	No	Unknown	
*The term "atherosclerotic cardiovascular disease" will be explained as having one of the following conditions:			
• Coronary artery disease (Including myocardial infarction, chronic unstable angina, having revascularization or coronary artery bypass graft operation previously)			
• Peripheral artery disease			
• Cerebrovascular disease			
• Aortic aneurysm			

**Statistical analysis**


All data were recorded on a computer database and analyzed using PASW Statistics for Windows, Version 18.0. (SPSS Inc., Chicago, IL, USA). Results

were expressed as mean±SD. The variables were assessed for normality using the Kolmogorov–Smirnov test, and Levene’s test was used to evaluate the equality of variance. Intergroup differences were analyzed

with a chi-squared test. A Kruskal-Wallis test was run to determine if there were differences in the LDL-C level according to FH status (i.e., definite, probable, possible). Pairwise comparisons were performed using Dunn's procedure with a Bonferroni correction for multiple comparisons. Differences were considered significant at a p value of <0.05.

## RESULTS


A retrospective laboratory survey of 16 months identified a total of 395 (0.6%) adult patients with an LDL-C level over 250 mg/dL among 65,320 LDL-C records. Ninety-eight patients were excluded due to the criteria previously described. In all, 297 individuals were enrolled in the study and were called by the medical students. Three of these patients were reported to have died (traffic accident, myocardial infarction, and cause of death not identified) by relatives, 135 individuals could not be reached, and 12 patients did not want to participate in the study. Finally, 147 patients (mean age:  $51.7 \pm 16.6$  years; 59.2% female) were interviewed, and the study questionnaire forms were completed (Fig. 1). About 75% of these patients were referred from 5 outpatient units (endocrinology, internal medicine, cardiology, cardiovascular surgery, and neurology). The clinical and demographic parameters of these patients were not significantly different from other outpatient units.




**Figure 1.** The study flow chart and an illustration of the approach used to identify patients with familial hypercholesterolemia from the data of central laboratory.

According to the DLCN criteria, the percentage of patients with definite FH (DLCN score >8), probable FH (DLCN score 6–8), and possible FH (DLCN score 3–5), was 18.4%, 66.0%, and 15.6%, respectively. Although the majority of the patients (93.9%) were aware that they had a high LDL-C level, only about half of these patients (n=75; 51.0%) were under treatment (Table 2).

The mean LDL-C level was  $292.8 \pm 49.9$  mg/dL. The median LDL-C level was significantly different between groups ( $H=41.721$ ;  $p<0.005$ ). Pairwise comparisons revealed that the differences between definite and possible FH ( $p<0.005$ ), and definite and probable FH ( $p<0.005$ ), were statistically significant, whereas the difference between probable and possible FH was not significant ( $p=0.964$ ). There were no significant



**Figure 2.** A graphic illustrating statin usage among patients with dyslipidemia.



**Figure 3.** The reasons for discontinuing use of lipid-lowering drugs in familial hypercholesterolemia patients.

**Table 2.** Demographic and laboratory characteristics of patients with definite, probable, and possible familial hypercholesterolemia

	All patients	Definite FH	Probable FH	Possible FH	p
Number (%)	147 (100%)	27 (18.4%)	97 (66%)	23 (15.6%)	
Gender (% women)	59.2	48.1	61.9	60.9	0.43*
Age (years)	51.7 ( $\pm$ 16.6)	43.2 ( $\pm$ 18.1)	53.4 ( $\pm$ 16.2)	54.6 ( $\pm$ 13.7)	<b>0.012**</b>
LDL-C (mg/dL)	292.8 ( $\pm$ 49.9)	359.5 ( $\pm$ 65.6)	279.4 ( $\pm$ 29.8)	271.1 ( $\pm$ 28.6)	<b>&lt;0.001***</b>
Smoking (%)	32.7	40.7	32.0	26.1	0.92****
Diet (%)	44.9	51.9	43.3	43.5	0.72*
Physical activity (%)	68.0	77.8	67.0	60.9	0.58*
Awareness of high LDL-C (%)	93.9	92.6	95.9	87.0	0.36****
Statin treatment (%)	51.0	48.1	53.6	43.5	0.64*
Treatment naive (%)	21.1	14.8	18.6	39.1	0.06*
Family history of premature CAD (%)	48.3	74.1	51.5	4.3	<b>&lt;0.001****</b>
Family history of dyslipidemia (%)	68.7	92.6	77.3	4.3	<b>&lt;0.001****</b>
Personal history of premature CAD (%)	26.5	29.6	32.0	0	<b>0.007*</b>

FH: Familial hypercholesterolemia; CAD: Coronary artery disease; LDL-C: Low-density lipoprotein cholesterol.

\*Chi-square test; \*\*Analysis of variance test; \*\*\*Kruskal-Wallis test; \*\*\*\*Fisher's exact test.

differences in the clinical and demographic characteristics of the patients in these groups.

About half of the patients were not in treatment (n=72; 49%). Of these untreated patients, 43.1% (n=31) had never used any lipid-lowering drug, and 56.9% (n=41) had stopped using a lipid-lowering drug (Fig. 2). The primary reasons for discontinuing the drug were patient request (n=19; 46.3%), drug side effect (n=11; 26.8%), impact of the media (n=7; 17.1%), and suggestion of healthcare providers (n=4; 9.8%) (Fig. 3).

The smoking rate was highest among the definite FH cases, but it was not statistically significant. Thirty-two percent of the patients were not performing regular exercise, and 55% were not following a dietary program. Family history of premature CAD and dyslipidemia was significantly higher in patients with definite FH (p<0.001 for both); however, the prevalence of premature CAD was significantly higher in patients with probable FH (p=0.007) (Table 1).

## DISCUSSION

The results of this pilot study conducted at a tertiary center demonstrate that the majority of FH patients were aware that they had a very high LDL-C level. Yet, about half of them were not taking lipid-lower-

ing medication. About one-fifth of all these patients had never used a lipid-lowering drug. This study also showed that identification of patients with a high LDL-C level based on the records of the central laboratories may be a practical approach to identify individuals with undiagnosed or undertreated FH.

FH is one of the most common genetic disorders of lipid metabolism with an increased risk for atherosclerosis, premature CHD, and heart failure.<sup>[18,19]</sup> Life expectancy is significantly shortened due to cardiovascular disease in patients with undertreated FH. However, the majority of patients with FH are undiagnosed and patients who are diagnosed often are undertreated.<sup>[1,4,5,20]</sup> Unfortunately, neither the prevalence of FH, nor the clinical condition of these patients is clearly known in Turkey. There are few data, other than a genetic study<sup>[15]</sup> and a long-term follow-up study, about homozygous FH patients.<sup>[16]</sup> As a result of the high frequency of consanguineous marriage, the prevalence of FH is expected to be higher than in most other regions of the world.<sup>[21]</sup> A nationwide study, AHIT-2, designed to investigate the clinical and demographic characteristics of FH patients, is expected to be completed before the end of 2017.<sup>[22]</sup> Early recognition of FH is important, as statin treatment reduces the risk of cardiovascular disease and mortality in patients with FH.<sup>[23,24]</sup> However, there is

no systematic screening program in most countries. In this regard, central laboratories may play a pivotal role in the identification of patients with FH, as they measure the lipid profile of a large number of patients.<sup>[3,9,10]</sup> In the current study, we used the data of the central laboratory of our tertiary hospital and identified patients who have an LDL-C level above 250 mg/dL and made a telephone call to determine demographic characteristics and other information. About 85% of the participants were either definite or probable FH patients, according to the DLCN criteria.<sup>[17]</sup> None of the patients in the study had achieved target LDL-C level. Therefore, the results of this study are very important, as they helped us to identify undiagnosed and undertreated FH patients and understand the reasons behind the inadequate health support.

Statins are the basic treatment modality to reduce cardiovascular disease and the mortality risk in patients with FH. Numerous studies have demonstrated that the atherosclerotic burden in patients with FH is significantly reduced after the initiation of statin treatment.<sup>[25,26]</sup> The rate of use of lipid-lowering medications in FH patients differs in various reports. Knickelbine et al.<sup>[4]</sup> reported that two-thirds of patients with FH were on statin treatment in a large ambulatory study population. Similarly, in the study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH), it was reported that 70% of the patients with FH were on statins, with 80% achieving an LDL-C <100 mg/dL.<sup>[5]</sup> However, in a Danish study, about half of the patients with FH had taken statins.<sup>[6]</sup> From the present, small, single-center data, it is not possible to estimate the percentage of statin usage among FH patients in Turkey. Also, patients under statin treatment with lower LDL levels were probably ignored due to the enrollment criteria. However, our results clearly show that about one-fifth of the patients interviewed had never used any lipid-lowering medication at all.

Patients with dyslipidemia have various states of awareness about their condition. In the US population, almost half of the patients with dyslipidemia were aware of their disease.<sup>[27]</sup> However, only 10% to 20% of patients with dyslipidemia were aware of their disease in the Chinese population.<sup>[28,29]</sup> In the current study, about 90% of our patients were aware of having a very high LDL-C level. The awareness rate was similar in patients from different outpatient

units. Furthermore, there was no difference in awareness rate between the patients with possible, probable, or definite FH status. Using the registry of a tertiary center and including patients with a very high LDL-C level (LDL-C >250 mg/dL) may be the reason for this higher rate of awareness. However, although they knew that they had dyslipidemia, half of these patients were not under a lipid-lowering regimen. Moreover, the rate of lipid-lowering treatment did not differ between the 3 groups, despite the fact that the patients with definite FH had a higher LDL-C level, and greater family history of CAD and dyslipidemia. Patients within these 3 categories were also similar in terms of demographic and clinical characteristics.

Several reasons may explain the lack of adequate treatment in these patients. Patient concerns about the necessity of taking statins may be one of the most common. Worry about joint and muscle side effects of statins is also a very common reason. Finally, there is also a lack of knowledge about the efficacy and importance of statin treatment among healthcare providers.<sup>[7,8]</sup> Likewise, in the present study, there were patients who had stopped using lipid-lowering drugs at their own request, as a result of minor drug side effects, the negative impact of media reports, and even due to the suggestion of healthcare providers. In this regard, identifying patients with a very high LDL-C level using central laboratory records could be a useful and practical method to inform patients and healthcare providers about the treatment of FH.

### Study limitations

This study has a number of limitations. First, a large part of the study data was based on self-reported information and could be subject to recall bias. Second, a physical examination of the patients was not performed (e.g., tendon xanthoma, arcus cornea). Therefore, we did not include this information in the scoring, which may have led to an incomplete definition of FH case status. For this reason, some cases may have scored lower than they would have otherwise. Also, as the data were collected from patients of a tertiary hospital, the findings may not directly be extrapolated to the wider population of FH patients in Turkey. Finally, subjects under statin treatment who had an acceptable LDL-C level were not included as a result of the enrollment criteria of this study.

## Conclusion

The results of the present study indicate that detecting patients with a high LDL-C level using the records of the central laboratories may be a practical method to identify undiagnosed or undertreated FH patients. Since only half of the FH patients in this study were use lipid-lowering medication and none of them had their cholesterol level under control, this method should be generalized to centers in different regions of the country to have more comprehensive data about the reasons for underdiagnosis and undertreatment of FH in Turkey.

**Peer-review:** Externally peer-reviewed.

**Conflict-of-interest:** None declared.

**Authorship contributions:** Concept – A.S.; Design – A.S., C.H.; Supervision – Ö.A., C.B., A.S.; Materials – T.Ö., Ö.Ö.; Data collection &/or processing – C.H., H.B., Y.G., O.E.T., C.A., Z.T., H.G.; Analysis and/or interpretation – A.S., C.B., C.H.; Literature search – A.S., C.H.; Writing – A.S., C.B., C.H.

## REFERENCES

- Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *Eur Heart J* 2013;34:3478–90a. [CrossRef]
- Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. *Eur Heart J* 2008;29:2625–33. [CrossRef]
- Bell DA, Hooper AJ, Bender R, McMahon J, Edwards G, van Bockxmeer FM, et al. Opportunistic screening for familial hypercholesterolaemia via a community laboratory. *Ann Clin Biochem* 2012;49:534–7. [CrossRef]
- Knickelbine T, Lui M, Garberich R, Miedema MD, Strauss C, VanWormer JJ. Familial hypercholesterolemia in a large ambulatory population: Statin use, optimal treatment, and identification for advanced medical therapies. *J Clin Lipidol* 2016;10:1182–7. [CrossRef]
- Safarova MS, Liu H, Kullo IJ. Rapid identification of familial hypercholesterolemia from electronic health records: The SEARCH study. *J Clin Lipidol* 2016;10:1230–9. [CrossRef]
- Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. *J Clin Endocrinol Metab* 2012;97:3956–64.
- Harrison TN, Derose SF, Cheetham TC, Chiu V, Vansomphone SS, Green K, et al. Primary nonadherence to statin therapy: patients' perceptions. *Am J Manag Care* 2013;19:e133–9.
- Wouters H, Van Dijk L, Geers HC, Winters NA, Van Geffen EC, Stiggelbout AM, et al. Understanding Statin Non-Adherence: Knowing Which Perceptions and Experiences Matter to Different Patients. *PLoS One* 2016;11:e0146272. [CrossRef]
- Bell DA, Hooper AJ, Edwards G, Southwell L, Pang J, van Bockxmeer FM, et al. Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitioner. *Atherosclerosis* 2014;234:469–72. [CrossRef]
- Watts GF, Sullivan DR, van Bockxmeer FM, Poplawski N, Hamilton-Craig I, Clifton PM, et al. A model of care for familial hypercholesterolaemia: key role for clinical biochemistry. *Clin Biochem Rev* 2012;33:25–31.
- Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. *Eur Heart J* 2015;36:560–5. [CrossRef]
- de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). *Circulation* 2016;133:1067–72. [CrossRef]
- Liyanage KE, Burnett JR, Hooper AJ, van Bockxmeer FM. Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. *Crit Rev Clin Lab Sci* 2011;48:1–18. [CrossRef]
- Lahtinen AM, Havulinna AS, Jula A, Salomaa V, Kontula K. Prevalence and clinical correlates of familial hypercholesterolemia founder mutations in the general population. *Atherosclerosis* 2015;238:64–9. [CrossRef]
- Sözen MM, Whittall R, Oner C, Tokatli A, Kalkanoğlu HS, Dursun A, et al. The molecular basis of familial hypercholesterolaemia in Turkish patients. *Atherosclerosis* 2005;180:63–71. [CrossRef]
- Kayıkçıoğlu M, Kismalı E, Can L, Payzin S. Long-term follow-up in patients with homozygous familial hypercholesterolemia; 13-year experience of a university hospital lipid clinic. *Turk Kardiyol Dern Ars* 2014;42:599–611. [CrossRef]
- World Health Organization. Familial hypercholesterolemia: report of a second WHO Consultation. Geneva, Switzerland: World Health Organization; 1999 WHO publication No. WHO/HGN/FH/CONS/99.2. Available at: [http://apps.who.int/iris/bitstream/10665/66346/1/WHO\\_HGN\\_FH\\_CONS\\_99.2.pdf](http://apps.who.int/iris/bitstream/10665/66346/1/WHO_HGN_FH_CONS_99.2.pdf). Accessed Oct 4, 2017.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486–97. [CrossRef]

19. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. *JAMA* 1990;264:3018–24. [\[CrossRef\]](#)
20. Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, et al; Familial Hypercholesterolaemia Australasia Network Consensus Group (Australian Atherosclerosis Society). Familial hypercholesterolaemia: a model of care for Australasia. *Atheroscler Suppl* 2011;12:221–63. [\[CrossRef\]](#)
21. Kayıkçıoğlu M. Homozygous familial hypercholesterolemia. *Türk Kardiyol Dern Ars* 2014;42 Suppl 2:19–31.
22. Kayıkçıoğlu M, Tokgözoğlu L. The rationale and design of the national familial hypercholesterolemia registries in Turkey: A-HIT1 and A-HIT2 studies. *Türk Kardiyol Dern Ars* 2017;45:261–7. [\[CrossRef\]](#)
23. Verschmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. *BMJ* 2008;337:a2423. [\[CrossRef\]](#)
24. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. *Eur Heart J* 2008;29:2625–33. [\[CrossRef\]](#)
25. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol* 2011;5:S1–8. [\[CrossRef\]](#)
26. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;106:3143–421.
27. Rodriguez CJ, Cai J, Swett K, González HM, Talavera GA, Wruck LM, et al. High Cholesterol Awareness, Treatment, and Control Among Hispanic/Latinos: Results From the Hispanic Community Health Study/Study of Latinos. *J Am Heart Assoc* 2015;4. pii: e001867. [\[CrossRef\]](#)
28. He H, Yu YQ, Li Y, Kou CG, Li B, Tao YC, et al. Dyslipidemia awareness, treatment, control and influence factors among adults in the Jilin province in China: a cross-sectional study. *Lipids Health Dis* 2014;13:122. [\[CrossRef\]](#)
29. Cai L, Zhang L, Liu A, Li S, Wang P. Prevalence, awareness, treatment, and control of dyslipidemia among adults in Beijing, China. *J Atheroscler Thromb* 2012;19:159–68. [\[CrossRef\]](#)

**Keywords:** Familial hypercholesterolemia; laboratory records; telephone interview.

**Anahtar sözcükler:** Ailevi hiperkolestrolemi; laboratuvar kayıtları; telefon görüşmesi.